Watch the complete interview with Novo Nordisk CEO Lars Fruergaard Jørgensen after the corporate reported better-than-expected web revenue within the fourth quarter of 2024 amid hovering demand for its Wegovy weight problems medication, however forecast a slight slowdown in gross sales for 2025.